New Research Shows Biotechnology Industry Executives Cautiously Optimistic
Industry Standard Research (ISR) announced the launch of a new and complimentary research report titled 2009 Biotechnology Industry Pulse. This report documents 112 biotech industry executives’ perspectives on the health and future of the biotechnology industry.
“Everyone has heard that access to capital has been severely restricted in the last year. We were determined to uncover how, if at all, this scarcity of capital has impacted biotechnology companies’ clinical development activities and how long any disruptions might be expected to last”, explained Kevin Olson, President, Industry Standard Research. Olson went on to state, “The results of the study show that while development has slowed for many companies, those with solid compounds continue to receive high valuations and have, in many cases, even accelerated their development timelines.”
Also detailed in the report are executives’ assessments of, and predictions for, volatility and consolidation across the industry; confidence in the small, VC-funded biotech model; and their preferences for various types of development models for their products.
Kevin Olson, President ISR, further explains: “We were struck by just how varied executives are in their views on the industry and their preferences for development models are far from uniform. I believe there’s a tendency in the CRO community to view this as a homogeneous customer segment but the data clearly indicate otherwise.”
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
